Difference between revisions of "Isotretinoin (Accutane)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
== Patient Drug Information== | == Patient Drug Information== | ||
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018662s059lbl.pdf Isotretinoin (Accutane) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018662s059lbl.pdf Isotretinoin (Accutane) Package Insert]</ref> | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018662s059lbl.pdf Isotretinoin (Accutane) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018662s059lbl.pdf Isotretinoin (Accutane) Package Insert]</ref> | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1982-05-07: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' Ro 4-3780 | *'''Code name:''' Ro 4-3780 | ||
| Line 30: | Line 31: | ||
[[Category:FDA approved in 1982]] | [[Category:FDA approved in 1982]] | ||
| + | [[Category:EMA approved in 1982]] | ||
Latest revision as of 15:10, 15 June 2023
Mechanism of action
From the NCI Drug Dictionary: A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
Diseases for which it is used
Diseases for which it was used
Patient Drug Information
History of changes in EMA indication
- 1982-05-07: EURD
Also known as
- Code name: Ro 4-3780
- Generic names: 13-cis-retinoic acid, 13-cis-vitamin A acid, 13-CRA, cis-retinoic acid, isotretinoinum, neovitamin A
- Brand names: Absorica, Accure, Accutane, Amnesteem, Cistane, Claravis, Isotrex, Isotrexin, Myorisan, Oratane, Roaccutan, Roaccutane, Roacutan, Sotret, Zenatane